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Background
A synergic association between acetylsalycilic acid, acet-
aminophen, caffeine in doses 3-4 times lower than simi-
lar combinations and chlorpheniramine was patented
and marketed as analgesic drug. A previous study
proved the non-inferiority of a unique dose of treatment
using Algopirin®, versus Excedrin® similar association.
Aim of the research was to prove superiority of two
tablets Algopirin® versus one tablet Excedrin® in treat-
ing migraine.
Method
Patients treated two independent migraine episodes of at
least moderate intensity with Algopirin® in first period
and with Excedrin® (Novartis) in second period. All
patients recorded the pain severity on a Visual Analog
Scale before and 30, 60, 120, 180 and 240 min after
drug intake. Comparison of the mean pain intensities
was performed using paired t test and Wilcoxon pair
signed rank test. Interpretation of pain curves as “survi-
val pain curves” allowed application of statistical meth-
ods usual in cancer research. Comparison of areas
under curves was performed similar with comparison of
plasma levels of drugs in pharmacokinetics.
Results
Effect of Algopirin® was greater than that of Excedrin®.
Mean time to 50 % (T50) pain relief was 30 min for
Algopirin® and 45 min for Excedrin. Time to pain relief
to 20 % (T20) was 85 min for Algopirin® and 180 min
for Excedrin®. Difference between effects measured by
areas under curves was 11%. All differences were statis-
tically significant (p < 0.01).
Conclusions
In spite of the fact that Algopirin® contains lower doses
of active components, its effect on pain curves in
migraine is superior to Excedrin®.
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